










REVIEW

Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations

Kristin A. Shimano¹  | Jennifer A. Rothman²  | Steven W. Allen³ | Paul Castillo⁴  |
Jill L. O. de Jong⁵ | Yigal Dror⁶  | Amy E. Geddis⁷ | Bonnie W. Lau⁸  |
Catherine McGuinn⁹ | Anupama Narla¹⁰ | Kathleen Overholt¹¹ | Maria A. Pereda¹² |
Anjali Sharathkumar¹³  | Ghadir Sasa¹⁴ | Taizo A. Nakano¹²  | Kasiani Myers¹⁵  |
Nicholas J. Gloude¹⁶ | Larisa Broglie¹⁷  | Jessica Boklan¹⁸

¹Department of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospital, San Francisco, California, USA

²Department of Pediatrics, Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, USA

³Department of Pediatrics, Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA

⁴Department of Pediatrics, Division of Pediatric Hematology Oncology, UF Health Shands Children's Hospital, Gainesville, Florida, USA

⁵Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, Illinois, USA

⁶Department of Pediatrics, Marrow Failure and Myelodysplasia Program, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada

⁷Department of Pediatrics, Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington, USA

⁸Department of Pediatrics, Pediatric Hematology-Oncology, Dartmouth-Hitchcock, Lebanon, New Hampshire, USA

⁹Department of Pediatrics, Division of Pediatric Hematology Oncology, Weill Cornell Medicine, New York, New York, USA

¹⁰Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA

¹¹Department of Pediatrics, Pediatric Hematology/Oncology, Riley Hospital for Children at Indiana University, Indianapolis, Indiana, USA

¹²Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, Colorado, USA

¹³Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

¹⁴Sarah Cannon Transplant and Cellular Therapy Network, San Antonio, Texas, USA

¹⁵Department of Pediatrics, University of Cincinnati College of Medicine, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

¹⁶Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, California, USA

¹⁷Department of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

¹⁸Department of Pediatrics, Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona, USA

Correspondence

Kristin Shimano, 550 16th St. Box 0434 San Francisco, CA 94143, USA.
Email: kristin.shimano@ucsf.edu

Abstract

Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management

Abbreviations: AA, aplastic anemia; AIEOP, Pediatric Haemato-Oncology Italian Association; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CNI, calcineurin inhibitor; CR, complete response; CSA, cyclosporine; Cy, cyclophosphamide; EBMT, European Group for Blood and Marrow Transplantation; EFS, event-free survival; FFS, failure-free survival; FlU, fludarabine; GCSF, granulocyte colony-stimulating factor; GVHD, graft versus host disease; hATG, horse-ATG; HLA, human leukocyte antigens; HSCT, hematopoietic stem cell transplant; IST, immunosuppressive therapy; MDS, myelodysplastic syndrome; MSD, matched sibling donor; NAPAAC, North American Pediatric Aplastic Anemia Consortium; NR, nonresponder; OR, overall response; OS, overall survival; PIGA, phosphatidylinositol glycan anchor biosynthesis class A; PNH, paroxysmal nocturnal hemoglobinuria; PR, partial response; QOL, quality of life; rATG, rabbit-ATG; RCT, randomized controlled trial; RD, refractory disease; SAA, severe aplastic anemia; TPO, thrombopoietin; TPO-RA, thrombopoietin receptor agonist; UCB, umbilical cord blood.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2024 The Authors. *Pediatric Blood & Cancer* published by Wiley Periodicals LLC.

approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up-to-date evidence-based approach to the treatment of children with newly diagnosed SAA.

KEYWORDS

aplastic anemia, bone marrow failure, pediatric hematology/oncology

1 | INTRODUCTION

Severe aplastic anemia (SAA) is an acquired bone marrow failure disorder caused by immune-mediated destruction of hematopoietic cells. It is characterized by pancytopenia and bone marrow hypoplasia as defined using the modified Camitta criteria, without evidence of underlying inherited bone marrow failure or myelodysplastic syndrome (MDS) (Table 1).¹ The North American Pediatric Aplastic Anemia Consortium (NAPAAC) recently published recommendations for evaluation of children with suspected SAA.²

Aplastic anemia was first described based on the marrow findings at autopsy in a patient by pathologist Paul Ehrlich in 1888.⁴ Treatments with androgens were reported in the 1960s, but median survival with supportive care, steroids, and androgens was less than 6 months.⁵ A syngeneic transplant for aplastic anemia was first performed in 1962, and allogeneic transplants were performed starting in the early 1970s.⁶ Based on evidence for an immune-mediated etiology, the use of antilymphocyte globulin (ATG) was trialed in the late 1970s. Cyclosporine was reported as a successful treatment in 1984.⁷

Today, for pediatric patients with newly diagnosed SAA, curative treatment options include hematopoietic stem cell transplant (HSCT) and immunosuppressive therapy (IST), with excellent overall survival (OS). NAPAAC previously published survey results from member institutions regarding diagnosis and management of SAA.⁸ Areas of controversy included the definition of treatment failure, use of hematopoietic growth factors, and preferred rescue therapy. The Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP) published diagnostic and management guidelines in 2015.⁹ In 2017, UK-based pediatric aplastic anemia (AA) experts amended the 2016 adult British Society of Hematology AA guidelines.^{10,11} With recent changes in treatment approaches for SAA in adults, there is a need for North American pediatric-specific recommendations.¹² This paper addresses the management of newly diagnosed SAA. A companion publication addresses the management of relapsed and refractory SAA.

2 | METHODS

NAPAAC membership includes pediatric hematologists, hematopoietic stem cell transplanters, and hematopathologists representing 56 institutions across North America where patients are treated for bone marrow failure. A subgroup of 19 members (representing 18 institutions) of the NAPAAC Acquired AA Working Group, all with significant experience caring for patients with SAA, identified important treatment issues to be addressed, then conducted a literature review using PubMed, supplemented with additional relevant sources, using search terms pertinent to each section of the recommendations. Summary recommendations using the GRADE process were graded as “strong” or “weak,” based on “high,” “moderate,” or “low” quality evidence (Table 2).^{13,14} When existing data from the literature were insufficient, recommendations were based upon available evidence in combination with expert opinion. An iterative process was used for formulation of recommendations and evidence grading until unanimous concordance amongst authors was reached. Reflecting the complexity of disease management, multiple areas where evidence is lacking, and rapidly evolving management approaches, acceptable alternative options were provided with the recommendations. Table 3 lists the summary of recommendations.

3 | FIRST-LINE TREATMENT

A retrospective analysis of children undergoing human leukocyte antigens (HLA) matched sibling donor (MSD) HSCT or IST between 1992 and 2009 showed similar OS (92 vs. 88%, no statistical difference) but with significantly better failure-free survival (FFS) in the MSD HSCT group (87 vs. 56%, $p < .0001$).¹⁵ The European Group for Blood and Marrow Transplantation (EBMT) similarly reported lower 3-year event-free survival (EFS) when IST was compared with MSD HSCT in both younger children (33% IST vs. 87% HSCT) as well as adolescents (64% IST vs. 83% HSCT).^{16,17} Therefore, MSD SCT remains the preferred treatment for patients newly diagnosed with SAA.

TABLE 1 Diagnostic criteria for severe aplastic anemia.³

Marrow cellularity	<25%, or 25–50% with <30% residual hematopoietic cells
Peripheral cytopenias (at least two of three)	
Absolute neutrophil count (ANC)	<0.5 × 10 ⁹ /L ^a
Platelets	<20 × 10 ⁹ /L
Absolute Reticulocyte Count	<60 × 10 ⁹ /L

^aANC < 0.2 × 10⁹/L defines very severe aplastic anemia (vSAA).

TABLE 2 Grading recommendations.

Grade	Definition
1A	Strong recommendation, high quality evidence
1B	Strong recommendation, moderate quality evidence
1C	Strong recommendation, low quality evidence
2A	Weak recommendation, high quality evidence
2B	Weak recommendation, moderate quality evidence
2C	Weak recommendation, low quality evidence
Quality of evidence	Definition
High quality	Well-designed RCTs
Moderate quality	RCTs with limitations; large, multiple, or well-designed observational studies
Low quality	Few or small observational studies, case reports; expert opinion weighing risks/benefits in absence of data

RCT, randomized controlled trial.

For patients without an available MSD, IST has historically been the first-line treatment.^{18,19} A recent meta-analysis of five retrospective studies (four of which included pediatric patients), totaling 343 patients, found pooled 5-year OS favoring up-front alternative-donor (source other than MSD) HSCT over IST, with a pooled odds ratio of 0.44 (95% confidence interval 0.23–0.85; $p = .01$).²⁰ However, four of the five studies included rabbit ATG in their IST comparator arm, so the IST results may have been suboptimal.^{21–24} The 5th study, from the EBMT, compared a pediatric cohort of 29 patients transplanted upfront with matched unrelated donor (MUD) HSCT to matched historical controls who had undergone either MSD HSCT, IST with horse-ATG, or HSCT following unsuccessful IST.²⁵ Two-year OS was comparable in all of the upfront treatment groups (96% MUD, 91% MSD, 94% IST), and 2-year EFS was better in the upfront MUD cohort compared with IST (92 vs. 40%, $p = .0001$), though the 40% 2-year EFS for IST was lower than would be expected. Some centers now opt for upfront MUD

HSCT. Recent trials have also explored the use of alternative donor HSCT for initial treatment of SAA.²⁶ However, graft versus host disease (GVHD), graft rejection, treatment-related mortality, and risk for infertility remain concerns. NAPAAC is conducting a randomized controlled trial (RCT) comparing the use of upfront MUD transplants to IST for pediatric patients with SAA (NCT05600426).²⁷ Until data from this trial are available, the current standard for first-line treatment for pediatric patients with SAA in North America is MSD HSCT. If no MSD is available, then the first-line treatment recommended is IST (Figure 1).

We recommend the use of MSD stem cell transplant for first-line therapy for pediatric patients with SAA (grade 1A).

Until data from ongoing trials are available, we recommend IST for first-line therapy for pediatric patients with SAA without an available MSD (grade 2A).

In some clinical settings, MUD HSCT may be a reasonable alternative to IST (grade 2C).

3.1 | MSD transplant

Outcomes in the MSD setting are excellent with OS rates approaching 90% or greater.^{16,28} Choice of conditioning regimen is dependent upon donor availability and stem cell source. In the setting of a MSD, cyclophosphamide (Cy), and antithymocyte globulin (ATG) with or without fludarabine (Flu) are the most commonly used regimens, with similar excellent outcomes (91% 5-year OS).^{29–31} Alemtuzumab-based conditioning regimens with Flu and Cy also have excellent OS.³²

Bone marrow is the preferred stem cell source for both MSD and MUD transplant for SAA. Peripheral blood stem cells are associated with lower survival and increased risk of chronic GVHD.^{33–35} MSD umbilical cord blood (UCB) is also not favored, although there are retrospective data supporting its use as well as case reports documenting successful use of combination of marrow and UCB in settings of size mismatch.^{36,37} Additionally, fresh rather than cryopreserved product should be used whenever possible due to higher incidence of 1-year graft failure and mortality in the latter.³⁸ Current standard prophylaxis for GVHD are calcineurin inhibitor-based regimens that also include methotrexate or mycophenolate mofetil.

We recommend the use of MSD HSCT with a nonmyeloablative conditioning regimen (grade 1B).

We recommend the use of bone marrow over other stem cell sources (grade 1B).

We recommend the use of fresh over cryopreserved stem cell product (grade 1B).

3.2 | Immunosuppressive therapy

Standard IST for SAA includes ATG in combination with CSA (Table 4).

TABLE 3 Summary of recommendations.

Recommendation	Grade
First-line treatment	
We recommend the use of MSD stem cell transplant for first-line therapy for pediatric patients with SAA.	1A
Until data from ongoing trials are available, we recommend IST for first-line therapy for pediatric patients with SAA without an available MSD.	2A
In some clinical settings, MUD HSCT may be a reasonable alternative to IST.	2C
Matched sibling donor transplant	
We recommend the use of MSD HSCT with a nonmyeloablative conditioning regimen.	1B
We recommend the use of bone marrow over other stem cell sources.	1B
We recommend the use of fresh over cryopreserved stem cell product.	1B
Immunosuppressive therapy	
We recommend the use of hATG in combination with CSA for first-line immunosuppressive therapy.	1A
rATG may be considered in settings where hATG and HSCT are not available options.	2B
We recommend beginning administration of CSA on day one of ATG treatment.	1B
We recommend a CSA goal trough level of 200–350 ng/mL, monitoring serum creatinine and bilirubin levels, and adjusting the dose and goal levels based on response and toxicities.	1C
For patients unable to tolerate CSA, we recommend tacrolimus as an alternative.	2C
We recommend use of steroids with ATG for prevention of serum sickness.	1C
We recommend a short (4–14 day) course of 2 mg/kg/day steroids followed by a taper over a minimum of 2 weeks to prevent serum sickness and other ATG-related reactions.	2C
Thrombopoietin receptor agonists	
We do not recommend the routine addition of eltrombopag to IST for pediatric patients with newly diagnosed SAA. Further research is needed to identify a sub-population who may benefit.	2B
Supportive care	
We recommend against the routine use of GCSF.	2A
Tapering calcineurin inhibitor	
We recommend tapering after a minimum of 6 months treatment and a CR with stable counts for 3–6 months	1C
For patients who tolerate the CSA taper, we recommend tapering the daily dose at a rate of 5–15% per month, with some patients requiring a longer taper. The tapering schedule should be adjusted based on the patient's ongoing blood counts in response to the taper and CSA toxicity.	1C
Paroxysmal nocturnal hemoglobinuria	
For patients without a MSD, we recommend IST for SAA with a PNH clone, regardless of clone size.	2B
In some clinical settings, MUD HSCT may be a reasonable alternative to IST to both treat SAA and eliminate any PNH clone.	2C
We recommend considering the use of complement inhibition concurrently with therapy for SAA in children with large ($\geq 30\%$) or symptomatic PNH clone.	2C

ATG, anti-thymocyte globulin; CR, complete response; CSA, cyclosporine; GCSF, granulocyte colony stimulating factor; hATG, horse-ATG; HSCT, hematopoietic stem cell transplant; IST, immunosuppressive therapy; MSD, matched sibling donor; SAA, severe aplastic anemia; MUD, matched unrelated donor; rATG, rabbit-ATG; PNH, paroxysmal nocturnal hemoglobinuria.

3.2.1 | Antithymocyte globulin

ATG treats the autoimmune T-cell-mediated process underlying SAA. In 1978, several case reports documented efficacy of ATG in treating patients with AA, which was then followed by subsequent case series.^{39,40} An RCT of patients with moderate to severe AA showed that 11 of 21 patients who received ATG had sustained improvement in hematopoiesis within 3 months of treatment, compared with no patients on the control/supportive care arm ($p = .0005$).^{41,42} Since these initial studies, ATG has remained the backbone of IST regimens.

ATG is available in two formulations, horse- (hATG) and rabbit-derived (rATG), which have different immunosuppressive profiles.^{43–46} In a large prospective RCT, 120 patients aged 2–77 years were treated with either upfront hATG/CSA or rATG/CSA.⁴⁷ hATG led to superior 6-month response rates (68% hATG vs. 37% rATG) and increased OS (94–96% hATG vs. 70–76% rATG). Findings from additional pediatric retrospective studies were consistent.^{48–50}

While a range of doses of hATG were used in these studies (15 mg/kg \times 5d, 15 mg/kg \times 8d, 40 mg/kg \times 4d), standard dosing in combination with CSA is 40 mg/kg/dose daily for 4 days.^{51–53}




FIGURE 1 Treatment algorithm for severe aplastic anemia in children. Recommended treatment for pediatric patients with severe aplastic anemia, based on availability of donors and the individual patient's response to therapy. SAA, severe aplastic anemia; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplant; IST, immunosuppressive therapy; PR, partial response; CR, complete response; CNI, calcineurin inhibitor.

We recommend the use of hATG in combination with CSA for first-line IST (grade 1A).

rATG may be considered in settings where hATG and HSCT are not available options (grade 2B).

3.2.2 | Cyclosporine

Cyclosporine is a calcineurin inhibitor that suppresses T-lymphocyte activation. The combination of CSA and hATG for the treatment of AA has repeatedly been shown to be superior to treatment with ATG or CSA alone.^{51,54–58} An RCT in adults and children demonstrated improvement in median time to response (60 days for hATG + CSA

vs. 82 days for hATG, $p = .019$), overall response (OR) (65% for hATG + CSA vs. 31% for hATG, $p = .011$), and improved FFS (39% for hATG + CSA vs. 24% for hATG, $p = .04$).⁵⁶ While alternative timing of cyclosporine with respect to ATG treatment has been evaluated, simultaneous administration has been effective, well tolerated, and is widely accepted.⁵⁷

CSA is a “critical dosage drug” requiring individual patient dose adjustments to optimize immunosuppressive effects and avoid toxicity.⁵⁹ Achieving therapeutic levels of CSA for patients with SAA is crucial for maintaining a hematologic response. We recommend a starting dose of 10–12 mg/kg divided twice daily. That starting dose may require adjustment if the patient is receiving concomitant medications, such as azoles for fungal prophylaxis, that interact through the

TABLE 4 Summary of IST regimen/supportive care.

Drug	Dose	Administration	Duration/comments
Treatment			
Antithymocyte globulin (horse)	40 mg/kg/dose every 24 h	Initial dose: IV over 8–10 h Subsequent doses: IV over 6–8 h Rate may be slowed based on patient tolerance of infusion	Days 1–4 Patients should be hospitalized during hATG infusions and monitored closely for infusion reactions and/or serum sickness. There is no evidence supporting a role for intradermal skin testing prior to ATG administration. Monitor platelet count daily during ATG
Methylprednisolone	1 mg/kg/dose every 12 h	IV	Days 1–4 One dose can be given daily as hATG premedication or infused simultaneously with hATG. On Day 5, can change to PO prednisone to complete a 4–14 day course, followed by a minimum 2-week taper off.
Cyclosporine A	Starting dose 5–6 mg/kg every 12 h [Lower starting dose if patient on concomitant medications metabolized through CYP3A4 pathway, e.g., azoles]	PO	Start on Day 1 of ATG and continue until taper indicated or starting alternative treatment (see <i>Treatment Response</i> section). Monitor drug levels—adjust dose for goal level 200–350 ng/mL.
Supportive care			
Acetaminophen	15 mg/kg/dose (650 mg max dose)	PO/IV	Days 1–4 Give daily as hATG premedication then every 4–6 h through infusion and as needed.
H1 antihistamine (diphenhydramine or hydroxyzine)	1 mg/kg/dose (50 mg max dose)	PO/IV	Days 1–4 Give daily as hATG premedication then every 6 h through infusion and as needed.
GI prophylaxis with H2 blocker or proton pump inhibitor	Standard dosing	PO/IV	Start on Day 1 of ATG and continue until steroid wean completed.

CYP3A4 metabolism pathway. Therapeutic range for plasma trough levels have ranged from 75 to 400 ng/mL.^{57,60} Goal trough levels of 200–350 ng/mL are most commonly used, although with minimal supporting data. Goal levels for individual patients may be adjusted based upon response and drug toxicities such as renal insufficiency.

We recommend beginning administration of CSA on day one of ATG treatment (grade 1B).

We recommend a CSA goal trough level of 200–350 ng/mL, monitoring serum creatinine and bilirubin levels, and adjusting the dose and goal levels based on response and toxicities (grade 1C).

3.2.3 | Cyclosporine alternatives

Tacrolimus is increasingly used instead of CSA to prevent rejection and GVHD in solid organ and HSCT.^{61–65} While CSA is a nonribosomal peptide that binds cyclophilins, tacrolimus is a macrolide antibiotic that binds FK-binding protein. The overall side effects of both drugs are

similar, though tacrolimus treatment is associated with less gingival hyperplasia and hirsutism.

There are no published RCTs comparing CSA to tacrolimus. A single center, prospective cohort study of pediatric patients conducted between 2003 and 2008 compared eight patients receiving IST with tacrolimus to 13 historical controls receiving IST with CSA between 1990 and 2003. Tacrolimus was dosed at 0.15 mg/kg orally twice daily with no trough levels specified. Cohorts demonstrated similar complete response (CR) rates (88% for tacrolimus and 85% for CSA). Tacrolimus was well tolerated and none of the patients developed gingival hyperplasia or hirsutism. In contrast, all patients receiving CSA developed these two side effects. Data regarding renal toxicity were not collected systematically.⁶⁶

Similarly, results from a single center prospective study of adult patients treated with rATG and tacrolimus for 12 months were compared with historical controls treated with rATG and CSA. Tacrolimus trough levels were 8–12 ng/mL. Thirteen subjects with a median age of 26 years (range 15–53) were enrolled. The OR and CR rates of the tacrolimus group were 84% and 53%, respectively. The OR and CR were comparable in the CSA group at 77 and 42%, respectively.⁶⁷

These results suggest that tacrolimus has lower rates of hirsutism and gingival hyperplasia, but no clear benefit for other CSA-related side effects. The overall disease response for tacrolimus is noninferior to CSA. Therefore, we recommend tacrolimus as an alternative to CSA for pediatric patients with SAA unable to tolerate CSA. Further study is recommended prior to utilizing tacrolimus for first line IST therapy.

Other alternatives to cyclosporine such as sirolimus have been reported.⁶⁸ The addition of sirolimus to standard IST showed no benefit in an RCT, and its role in the treatment of SAA is an area of investigation (NCT02979873).⁶⁹ Routine use of sirolimus is not recommended outside of a clinical trial.

For patients unable to tolerate CSA, we recommend tacrolimus as an alternative (grade 2C).

3.2.4 | Steroids

Corticosteroids have a supportive care role in the standard IST regimen for SAA. They are used to reduce the risk of serum sickness since both rATG and hATG can cause serum sickness in 25–75% of patients and, more rarely, anaphylaxis.^{44,70,71} As a foreign protein, ATG elicits immune response in humans with immune complexes usually forming by 10 days after initiation of ATG. The most common manifestations are fever, arthralgia, malaise, rashes, lymphadenopathy, proteinuria and, in severe cases, acute renal failure.^{72,73} Feng et al.⁴⁴ reported serum sickness in 25% of patients treated with rATG versus 15% of those treated with hATG. A multicenter study using ATG in renal transplantation reported a 7.5% incidence of serum sickness at a median onset of 11 days, despite the administration of steroids.⁷⁴

NAAPAC centers reported the use of 2 mg/kg/day of methylprednisolone during ATG infusion followed by oral prednisone for a total 4–14 day steroid course followed by a taper.⁸ There is no consensus regarding the total length of steroid course. Two-week courses of steroids have been used by some groups, while others favor longer tapering courses over 30 days after ATG.^{18,75–78} There is no clinical evidence showing the benefits of a short versus longer course of steroids in patients receiving IST for SAA. If patients develop signs or symptoms of serum sickness, the steroid dose may need to be increased or the taper prolonged.

We recommend use of steroids with ATG for prevention of serum sickness (grade 1C).

We recommend a short (4–14 day) course of 2 mg/kg/day steroids followed by a taper over a minimum of 2 weeks to prevent serum sickness and other ATG-related reactions (grade 2C).

3.3 | Thrombopoietin receptor agonists

Thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, have emerged as promising therapeutic options for AA as

their actions extend beyond megakaryopoiesis to affect trilineage responses.^{79,80} Preclinical studies show that thrombopoietin (TPO) induces hematopoietic stem cell progenitors through binding its receptor, *c-mpl*.^{81–83}

Eltrombopag is United States Food and Drug Administration approved for treatment of newly diagnosed SAA in conjunction with IST in patients over 2 years old.⁸⁴ The approval was based on an NIH study, which included both pediatric and adult patients and showed a significant increase in response at 6 and 12 months for patients who received IST plus eltrombopag compared with historical controls.⁸⁵ A subsequent RCT by the EBMT confirmed benefit of eltrombopag when added to hATG/CSA in patients greater than 15 years old, with significantly shorter median time to first hematologic response and CR compared with patients who received hATG/CSA alone.^{86,87} EFS was higher in the eltrombopag group, although OS was not different. Toxicity, including development of somatic mutations or cytogenetic changes, was not increased by the addition of eltrombopag.

Despite these significant results in adults, the benefit of adding eltrombopag to standard IST in children with SAA is less clear. A subgroup analysis of the 40 pediatric patients (aged <18 years) in the NIH study did not show any improvement in outcomes versus historical controls for children who received eltrombopag in addition to hATG/CSA with OR at 6 months 70 versus 72% ($p = .78$), and 4-year EFS in responders 57 versus 69% ($p = .0499$).⁸⁸ The discrepancy between pediatric and adult results may be due to better baseline response to IST in children. OR of pediatric historical controls was 72%, while that of adults was 58%. Additionally, there may be biologic differences in the SAA in children compared with adults that influences treatment response.⁸⁹ In the EBMT study, the pediatric population (aged 15–18 years) made up only 5% of the trial population ($n = 9$; seven receiving IST alone and two receiving eltrombopag).

Two prospective pediatric trials evaluating the addition of eltrombopag to IST were recently completed. In a joint North American/European multicenter single-arm phase 2 study (NCT03025698), children with de novo SAA ($n = 37$) treated with a combination of hATG/CSA/eltrombopag demonstrated an OR of 46% at 6 months.⁹⁰ While the study was not powered for a formal statistical analysis to compare with historical controls, the OR was clearly no better than in previous extensive experience with hATG/CSA alone. Hepatotoxicity included elevated bilirubin in 43% and elevated ALT in 41% of patients with 7 patients discontinuing eltrombopag due to liver toxicity. Two of 37 patients developed new chromosomal abnormalities—one with a transient +Y at week 26 and another with a $t(2;3)(p23;q12)$ at week 182.

A Russian RCT (NCT03413306) compared hATG/CSA with hATG/CSA/eltrombopag.⁹¹ For the primary endpoint of OR at 4 months, there was no difference between the groups (65% for eltrombopag arm vs. 53% for IST only arm; $p = .28$). There was a higher CR rate of 31% for the patients who received eltrombopag versus 12% for the IST only arm ($p = .027$) at 4 months. Three-year EFS (41% IST, 53% IST/eltrombopag; $p = .326$) and OS (91% IST, 89% IST/eltrombopag; $p = .673$), were the same for both arms, though an atypical cross-over

design at 6 months makes that difficult to interpret. Two patients on the IST only arm developed monosomy 7. One patient treated with IST/eltrombopag developed a transient der(9) del(9q). Grade 3–4 hepatotoxicity was observed in 33% patients receiving IST alone compared with 61% of patients who received eltrombopag ($p = .005$). While eltrombopag may have benefited certain subgroups, study limitations make it difficult to draw specific conclusions.

While emerging data look promising for the use of TPO-RAs in some settings, unanswered questions remain. Dosing regimen and duration of therapy as well as long-term safety need to be clarified in pediatric patients, particularly regarding clonal evolution. The appropriate subsets of pediatric patients who would benefit, either by using eltrombopag as monotherapy or in conjunction with IST, need to be identified.

We do not recommend the routine addition of eltrombopag to IST for pediatric patients with newly diagnosed SAA. Further research is needed to identify a sub-population who may benefit (grade 2B).

3.4 | Supportive care

3.4.1 | Granulocyte colony-stimulating factor

Historically, granulocyte colony-stimulating factor (GCSF) has been used in patients with SAA.

In 2011, the EBMT published results from a RCT of 192 patients with SAA who were treated with ATG/CSA and then randomized to \pm GCSF (dose of 150 mcg/m²/d). There was no difference in OS or EFS, remission, relapse rates or mortality. However, a post hoc analysis found that patients receiving GCSF had fewer infections compared with controls, especially for patients with very SAA (vSAA).⁹² Patients treated with GCSF also had fewer hospitalization days. Long-term follow-up published in 2020 showed no significant difference in OS, EFS, or the incidence of MDS, acute myeloid leukemia, isolated cytogenetic abnormalities, solid cancer, clinical paroxysmal nocturnal hemoglobinuria (PNH), aseptic necrosis, or relapse.^{92,93}

In 2014, a Chinese group published results from a RCT looking at four different regimens for pediatric SAA with IST with or without GCSF. GCSF neither contributed to early response nor reduced the infection rate, infection-related death rate, or the patients' long-term survival. There were no significant differences in OS among the four groups.⁹⁴

Taken together, the current data do not support the routine use of empiric GCSF upfront in SAA, with several caveats. Treatment does not appear to be harmful and lacks long-term effects. There may be a role for GCSF in certain patients with vSAA or active infections. These are important areas for future studies.

We recommend against the routine use of GCSF (grade 2A).

3.4.2 | Other supportive care

Other supportive care issues include transfusion criteria, central line preferences, fever management, infection prophylaxis, oral hygiene, immunization practices, management of iron overload, and long-term follow-up. These are beyond the scope of this paper but will be the subject of future NAPAAC recommendations.

4 | TREATMENT RESPONSE

4.1 | Definition of response

Quantitative hematologic response: In 2000, Camitta⁹⁵ defined CR as both transfusion independence and complete normalization for age of all three peripheral blood cell lines. Many have adapted pediatric SAA response criteria to accept lesser peripheral blood values that simply no longer meet blood count criteria of SAA.¹⁸ More recent manuscripts define CR by specific criteria for each cell line (Table 5).⁵² Quantitative assessment should occur off all colony-stimulating factors. Response should be sustained by two or more CBCs at least four weeks apart before assigning an IST response category.

Qualitative hematologic response: The quality of a response and the effect on a patient's quality of life (QOL) are important in assessing whether additional therapy is required after up-front IST. Independence from red blood cell and platelet transfusions and immunologic recovery that allows participation in daily activities are broad response categories influencing disease morbidity.

4.2 | Tapering calcineurin inhibitor

Historically, CSA was discontinued shortly after response or after 6 months of treatment.^{51,55} However, disease recurrence was common with abrupt discontinuation. The NIH eltrombopag trial had high rates of relapse with discontinuation of CSA after 6 months, so was amended to continue CSA for a total of 24 months. The EBMT eltrombopag trial used CSA at fixed dosing for a minimum of 12 months followed by tapering over 12 months.^{85,87} A retrospective AIEOP study of 42 children with AA treated with IST including CSA 5 mg/kg/day examined CSA tapering schedules beginning after at least 6 months of therapy and a minimum of 3 months of stable blood counts. There was a 7.6% incidence of relapse in the slow taper group (<0.3–0.7 mg/kg/month) compared with 60% in the rapid taper group (0.8 mg/kg/month), $p = .001$.⁶⁰

The optimal duration of CSA treatment for each patient should consider duration of treatment and response. Tapering may begin after a minimum of 6 months of treatment and CR with stable counts for 3–6 months. If patients have a PR by 6 months and are continuing to have steady improvement in counts, treatment should be continued without tapering. If counts have plateaued for 3 months with a PR, HSCT donor options, side effects and toxicity of the treatment, QOL, and

TABLE 5 IST response criteria.

	Transfusion status	ANC	Hemoglobin	Platelet count
Complete response (CR)	Independent	$\geq 1 \times 10^9/L$	and ≥ 10 g/dL	and $\geq 100 \times 10^9/L$
Partial response (PR)	Independent	$\geq 0.5 \times 10^9/L$	and ≥ 8 g/dL	and $\geq 20 \times 10^9/L$
Nonresponder (NR) or refractory disease (RD)	Dependent	or $< 0.5 \times 10^9/L$	or < 8 g/dL	or $< 20 \times 10^9/L$

other goals of care should be considered prior to initiating a taper. Of note, some patients are CSA dependent to maintain blood counts and will be unable to taper off the drug.⁶⁰ As long as CSA is well tolerated, it can be continued indefinitely, with consideration of the risk: benefit analysis of indefinite CSA treatment versus definitive therapy, such as HSCT.

For patients using tacrolimus in lieu of CSA, we recommend a similar tapering approach.

Recommendations for patients who do not respond or relapse after initial response are described in the companion manuscript on treatment of relapsed/refractory SAA.

We recommend tapering CSA after a minimum of 6 months treatment and a CR with stable counts for 3–6 months (grade 1C).

For patients who tolerate the CSA taper, we recommend tapering the dose at a rate of 5–15% per month, with some patients requiring a longer taper. The tapering schedule should be adjusted based on the patient's ongoing blood counts and CSA toxicity (grade 1C).

5 | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

PNH is an acquired clonal stem cell disorder with clinical manifestations of hemolytic anemia, thrombosis, and progression to acquired AA. In PNH, somatic mutation of the phosphatidylinositol glycan anchor biosynthesis class A (PIGA) gene occurs in hematopoietic stem cell subclones resulting in loss of glycosylphosphatidylinositol-anchored proteins, including CD55 and CD59, on the surface of hematopoietic cells, leading to increased complement-mediated lysis. Treatment of classical PNH with eculizumab, a monoclonal humanized antibody which inhibits C5 complement, decreases intravascular hemolysis and reduces risk of thrombosis.^{96–98}

In a multi-institutional retrospective study of children with SAA, NAPAAC reported that 39% (55 of 140) had a detectable PNH clone.⁵² In this study, the majority of patients had a small clone size, with only 5 children having a PNH clone $> 10\%$ (range: 12.56–28.4%).

Reports indicate that patients with SAA who have a PNH clone respond better to IST than patients without a PNH clone, regardless of clone size.^{99–103} There are no randomized clinical trials to compare outcomes of patients with SAA and a PNH clone who are treated

with IST versus HSCT. Likewise, there are no clear recommendations for treatment of patients with a rapidly increasing PNH clone without major symptomatology. Therefore, treatment decisions are based on the clinical presentation and symptoms.

There are no published guidelines for the treatment of AA and a concomitant PNH clone or symptomatic PNH disease. No studies define a clone size cutoff that would support adding eculizumab, but rather refer to patients with a “significant clone,” generally defined as causing clinically significant hemolysis and/or thrombosis. Moderate sized clones of 30–50% present in patients with marrow failure may cause symptoms.¹⁰⁴

Eculizumab for the management of large PNH clones while undergoing definitive management with IST for bone marrow failure has been described in case reports and small case series. Either concurrent or sequential eculizumab therapy in adults and children had no unexpected side effects.^{105–107} New inhibitors of terminal complement to manage classical PNH include ravulizumab, crovalima, and pegcetacoplan.^{108–110} However, there are currently no pediatric data for these agents in patients with AA.¹¹¹

For patients without a MSD, we recommend IST for SAA with a PNH clone, regardless of clone size (grade 2B).

In some clinical settings, MUD HSCT may be a reasonable alternative to IST to both treat SAA and eliminate any PNH clone (grade 2C).

We recommend considering the use of complement inhibition concurrently with therapy for SAA in children with large or symptomatic PNH clone (grade 2C).

6 | CONCLUSION/FUTURE DIRECTIONS

SAA is a rare hematologic disorder in children. Here, we have evaluated available evidence, bolstered by expert opinion where evidence is lacking, to provide recommendations for different aspects of treatment of newly diagnosed SAA in North American children. Individual institutional approaches must consider local expertise as well as patient-specific clinical circumstances. We advocate for pediatric clinical trials in SAA to continue improving outcomes and provide data necessary for future development of exclusively evidence-based treatment guidelines. While supportive care recommendations are beyond the scope of this paper, they are a critical component of AA treatment that we plan to address in future publications.

CONFLICT OF INTEREST STATEMENT

Research funding—Novartis: KAS. Research funding—Amgen, Inc.: AS. Research funding—Incyte, Elixigen Therapeutics: KM. Research funding—Sanofi, Roche/Genentech/Spark,Takeda. Consulting/Medical Advisory Board—Genentech, BPL, CSL, Hema Biologics, Bayer, Octapharma: CM. Consulting fees—RocketPharma: NJG.

FUNDING INFORMATION

None.

ORCID

Kristin A. Shimano  <https://orcid.org/0000-0001-8371-1040>

Jennifer A. Rothman  <https://orcid.org/0000-0003-1582-2886>

Paul Castillo  <https://orcid.org/0000-0002-2813-1729>

Yigal Dror  <https://orcid.org/0000-0003-3953-1477>

Bonnie W. Lau  <https://orcid.org/0000-0003-2688-437X>

Anjali Sharathkumar  <https://orcid.org/0000-0003-4574-6175>

Taizo A. Nakano  <https://orcid.org/0000-0003-0389-2297>

Kasiani Myers  <https://orcid.org/0000-0002-5528-4405>

Larisa Broglie  <https://orcid.org/0000-0002-1674-048X>

REFERENCES

- Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. *Blood*. 1976;48(1):63-70.
- Shimano KA, Narla A, Rose MJ, et al. Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium. *Am J Hematol*. 2021;96(11):1491-1504.
- Rovo A, Tichelli A, Dufour C, Saa-Wp E. Diagnosis of acquired aplastic anemia. *Bone Marrow Transplant*. 2013;48(2):162-167.
- Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. *N Engl J Med*. 1982;306(11):645-652.
- Li FP, Alter BP, Nathan DG. The mortality of acquired aplastic anemia in children. *Blood*. 1972;40(2):153-162.
- Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. *N Engl J Med*. 1982;306(12):712-718.
- Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. *Semin Hematol*. 2000;37(1):56-68.
- Williams DA, Bennett C, Bertuch A, et al. Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). *Pediatr Blood Cancer*. 2014;61(5):869-874.
- Barone A, Lucarelli A, Onofrillo D, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Hemato-Oncology Italian Association (AIEOP). *Blood Cells Mol Dis*. 2015;55(1):40-47.
- Samarasinghe S, Veys P, Vora A, Wynn R. Paediatric amendment to adult BSH Guidelines for aplastic anaemia. *Br J Haematol*. 2018;180(2):201-205.
- Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. *Br J Haematol*. 2016;172(2):187-207.
- Young NS. Aplastic Anemia. *N Engl J Med*. 2018;379(17):1643-1656.
- Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-394.
- Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. *BMJ*. 2008;336(7652):1049-1051.
- Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. *Haematologica*. 2014;99(12):1784-1791.
- Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. *Br J Haematol*. 2015;169(4):565-573.
- Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014;99(10):1574-1581.
- Scheinberg P, Young NS. How I treat acquired aplastic anemia. *Blood*. 2012;120(6):1185-1196.
- Bacigalupo A. How I treat acquired aplastic anemia. *Blood*. 2017;129(11):1428-1436.
- Alotaibi H, Aljurf M, de Latour R, et al. Upfront alternative donor transplant versus immunosuppressive therapy in patients with severe aplastic anemia who lack a fully HLA-matched related donor: systematic review and meta-analysis of retrospective studies, on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation. *Transplant Cell Ther*. 2022;28(2):105.e101-105.e107.
- Cheng Y, Xu Z, Zhang Y, et al. First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. *Clin Transplant*. 2018;32(2).
- Choi YB, Yi ES, Lee JW, Sung KW, Koo HH, Yoo KH. Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor. *Bone Marrow Transplant*. 2017;52(1):47-52.
- Xu ZL, Zhou M, Jia JS, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. *Bone Marrow Transplant*. 2019;54(8):1319-1326.
- Yang S, Yuan X, Ma R, et al. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor. *Biol Blood Marrow Transplant*. 2019;25(5):975-980.
- Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. *Br J Haematol*. 2015;171(4):585-594.
- DeZern AE, Zahurak M, Symons HJ, et al. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. *Blood*. 2023;141(25):3031-3038.
- Pulsipher MA, Lehmann LE, Bertuch AA, et al. A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium. *Pediatr Blood Cancer*. 2020;67(10):e28444.
- Bacigalupo A, Socie G, Hamladji RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. *Haematologica*. 2015;100(5):696-702.
- Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. *Blood*. 1994;84(3):941-949.

30. Bejanyan N, Kim S, Hebert KM, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. *Blood Adv.* 2019;3(20):3123-3131.
31. Takpradit C, Prockop SE, Kernan NA, et al. Allogeneic matched related donor bone marrow transplantation for pediatric patients with severe aplastic anemia using "low-dose" cyclophosphamide, ATG plus fludarabine. *J Pediatr Hematol Oncol.* 2018;40(4):e220-e224.
32. Marsh JC, Pearce RM, Koh MB, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2014;49(1):42-48.
33. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. *Blood.* 2011;118(9):2618-2621.
34. Bacigalupo A, Socie G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. *Haematologica.* 2012;97(8):1142-1148.
35. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. *Blood.* 2007;110(4):1397-1400.
36. Pagliuca S, Peffault de Latour R, Volt F, et al. Long-term outcomes of cord blood transplantation from an HLA-identical sibling for patients with bone marrow failure syndromes: a report from eurocord, cord blood committee and severe aplastic anemia working party of the european society for blood and marrow transplantation. *Biol Blood Marrow Transplant.* 2017;23(11):1939-1948.
37. Stepsensky P, Revel-Vilk S, Weintraub M, et al. Combination of umbilical cord blood with BM from a 2-month-old sibling as lifesaving BMT for very severe aplastic anemia. *Bone Marrow Transplant.* 2008;42(8):563-564.
38. Eapen M, Zhang MJ, Tang XY, et al. Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia. *Biol Blood Marrow Transplant.* 2020;26(7):e161-e166.
39. Amare M, Abdou NL, Robinson MG, Abdou NI. Aplastic anemia associated with bone marrow suppressor T-cell hyperactivity: successful treatment with antithymocyte globulin. *Am J Hematol.* 1978;5(1):25-32.
40. Pedersen-Bjergaard J, Ernst P, Nissen NI. Severe aplastic anaemia with complete autologous marrow reconstitution following treatment with antithymocyte globulin. Report of a case and review of the literature. *Scand J Haematol.* 1978;21(1):14-18.
41. Cairo MS, Baehner RL. The use of antithymocyte globulin in the treatment of severe aplastic anemia in children. *J Pediatr.* 1982;100(2):307-311.
42. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. *N Engl J Med.* 1983;308(3):113-118.
43. Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. *Blood.* 2007;109(8):3219-3224.
44. Feng X, Scheinberg P, Biancotto A, et al. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. *Haematologica.* 2014;99(9):1433-1440.
45. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. *J Am Soc Nephrol.* 2006;17(10):2844-2853.
46. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. *Blood.* 2008;111(7):3675-3683.
47. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *N Engl J Med.* 2011;365(5):430-438.
48. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. *Blood.* 2012;119(23):5391-5396.
49. Yoshimi A, Niemeyer CM, Fuhrer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. *Blood.* 2013;121(5):860-861.
50. Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. *Haematologica.* 2014;99(4):664-671.
51. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. *Blood.* 1995;85(11):3058-3065.
52. Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. *Haematologica.* 2019;104(10):1974-1983.
53. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. *JAMA.* 2003;289(9):1130-1135.
54. Frickhofen N, Kaltwasser JP. Immunosuppressive treatment of aplastic anemia: a prospective, randomized multicenter trial evaluating antilymphocyte globulin (ALG) versus ALG and cyclosporin A. *Blut.* 1988;56(4):191-192.
55. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. *N Engl J Med.* 1991;324(19):1297-1304.
56. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study G. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. *Blood.* 2003;101(4):1236-1242.
57. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. *Blood.* 1999;93(7):2191-2195.
58. Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. *Klin Padiatr.* 1998;210(4):173-179.
59. Morris RG. Cyclosporin therapeutic drug monitoring—an established service revisited. *Clin Biochem Rev.* 2003;24(2):33-46.
60. Saracco P, Quarello P, Iori AP, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. *Br J Haematol.* 2008;140(2):197-205.
61. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood.* 1998;92(7):2303-2314.
62. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. *Blood.* 2000;96(6):2062-2068.

63. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. *Cochrane Database Syst Rev.* 2006;2006(4):CD005161.
64. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. *Pediatr Nephrol.* 2002;17(3):141-149.
65. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. *J Heart Lung Transplant.* 1999;18(4):336-345.
66. Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. *Pediatr Blood Cancer.* 2009;52(5):626-630.
67. Zhu X, Guan J, Xu J, et al. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. *Blood Cells Mol Dis.* 2014;53(3):157-160.
68. Niu H, Qi W, Wang Y, et al. Successful sirolimus therapy of an aplastic anemia patient with chronic kidney disease: A case report. *Medicine (Baltimore).* 2020;99(23):e20669.
69. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. *Haematologica.* 2009;94(3):348-354.
70. Millar MM, Grammer LC. Case reports of evaluation and desensitization for anti-thymocyte globulin hypersensitivity. *Ann Allergy Asthma Immunol.* 2000;85(4):311-316.
71. Wolanin SA, Demain JG, Meier EA. Successful desensitization of a patient with aplastic anemia to antithymocyte globulin. *Allergy Rhinol (Providence).* 2015;6(1):64-67.
72. Chao YK, Shyr SD, Wu CY, Wang CY. Childhood serum sickness: a case report. *J Microbiol Immunol Infect.* 2001;34(3):220-223.
73. Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. *Liver Transpl.* 2007;13(5):647-650.
74. Teng J, Hoo XN, Tan SJ, Dwyer K. Serum sickness following rabbit anti-thymocyte globulin for acute vascular renal allograft rejection. *Clin Kidney J.* 2012;5(4):334-335.
75. Jie M, Fu L, Li S, et al. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. *Pediatr Hematol Oncol.* 2021;38(7):647-657.
76. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). *Blood.* 2000;95(6):1931-1934.
77. Dincol G, Aktan M, Diz-Kucukaya R, et al. Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin A, methylprednisolone, and granulocyte colony-stimulating factor. *Am J Hematol.* 2007;82(9):783-786.
78. Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. *Am J Hematol.* 2017;92(12):1295-1302.
79. Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. *Int J Hematol.* 2013;98(1):48-55.
80. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. *N Engl J Med.* 2012;367(1):11-19.
81. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. *Proc Natl Acad Sci USA.* 1998;95(3):1195-1200.
82. Zeigler FC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. *Blood.* 1994;84(12):4045-4052.
83. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. *Cell Stem Cell.* 2007;1(6):671-684.
84. FDA-Label-Search. Accessed November 30, 2023. <https://nctcrs.fda.gov/fdalabel/services/spl/set-ids/7714a0ed-34bb-46e6-a0a5-b363908b22c2/spl-doc?hl=eltrombopag>
85. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. *N Engl J Med.* 2017;376(16):1540-1550.
86. Scheinberg P. A new standard immunosuppression regimen in severe aplastic anemia. *N Engl J Med.* 2022;386(1):89-90.
87. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. *N Engl J Med.* 2022;386(1):11-23.
88. Groarke EM, Patel BA, Gutierrez-Rodriguez F, et al. Eltrombopag added to immunosuppression for children with treatment-naive severe aplastic anaemia. *Br J Haematol.* 2021;192(3):605-614.
89. Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. *Haematologica.* 2022;107(1):126-133.
90. Shimamura A, Maschan A, Bennett C, et al. Eltrombopag in pediatric patients with previously untreated or refractory/relapsed severe aplastic anemia: the Phase II escalate trial. *Blood.* 2022;140(Supplement 1):705-707.
91. Goronkova O, Novichkova G, Salimova T, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. *Blood Adv.* 2023;7(6):953-962.
92. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. *Blood.* 2011;117(17):4434-4441.
93. Tichelli A, de Latour RP, Passweg J, et al. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. *Haematologica.* 2020;105(5):1223-1231.
94. Liu X, Zou Y, Wang S, et al. Immunosuppressive therapy using antithymocyte globulin and cyclosporin A with or without human granulocyte colony-stimulating factor in children with acquired severe aplastic anemia. *Zhonghua Er Ke Za Zhi.* 2014;52(2):84-89.
95. Camitta BM. What is the definition of cure for aplastic anemia? *Acta Haematol.* 2000;103(1):16-18.
96. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. *Blood.* 2007;110(12):4123-4128.
97. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. *Am J Hematol.* 2010;85(8):553-559.
98. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood.* 2011;117(25):6786-6792.
99. Zhao X, Zhang L, Jing L, et al. The role of paroxysmal nocturnal hemoglobinuria clones in response to immunosuppressive therapy of

- patients with severe aplastic anemia. *Ann Hematol*. 2015;94(7):1105-1110.
100. Kulagin A, Lisukov I, Ivanova M, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. *Br J Haematol*. 2014;164(4):546-554.
 101. Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2012;97(11):1666-1673.
 102. Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. *Leukemia*. 2021;35(11):3223-3231.
 103. Stanley N, Olson TS, Babushok DV. Recent advances in understanding clonal haematopoiesis in aplastic anaemia. *Br J Haematol*. 2017;177(4):509-525.
 104. Babushok DV. When does a PNH clone have clinical significance? *Hematol Am Soc Hematol Educ Program*. 2021;2021(1):143-152.
 105. Sabet K, Panigrahi AR. Pediatric patients with severe aplastic anemia treated with combined immunosuppressive therapy, eltrombopag and eculizumab and their clinical course to stem cell transplant. *Blood*. 2020;136(Supplement 1):13-13.
 106. Alashkar F, Duhrsen U, Roth A. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? *Eur J Haematol*. 2016;97(4):403-405.
 107. Pagliuca S, Risitano AM, De Fontbrune FS, et al. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. *Bone Marrow Transplant*. 2018;53(1):105-107.
 108. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*. 2019;133(6):540-549.
 109. Roth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. *Blood*. 2020;135(12):912-920.
 110. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*. 2021;384(11):1028-1037.
 111. Risitano AM, Peffault de Latour R. How we(II) treat paroxysmal nocturnal haemoglobinuria: diving into the future. *Br J Haematol*. 2021;196(2):288-303.

How to cite this article: Shimano KA, Rothman JA, Allen SW, et al. Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations. *Pediatr Blood Cancer*. 2024;e31070. <https://doi.org/10.1002/pbc.31070>